These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 12761227)
1. Sequences within domain II of the urokinase receptor critical for differential ligand recognition. Li Y; Lawrence DA; Zhang L J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227 [TBL] [Abstract][Full Text] [Related]
2. Ligand binding regions in the receptor for urokinase-type plasminogen activator. Liang OD; Chavakis T; Kanse SM; Preissner KT J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527 [TBL] [Abstract][Full Text] [Related]
3. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128 [TBL] [Abstract][Full Text] [Related]
4. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding. Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826 [TBL] [Abstract][Full Text] [Related]
5. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. Gårdsvoll H; Ploug M J Biol Chem; 2007 May; 282(18):13561-72. PubMed ID: 17355965 [TBL] [Abstract][Full Text] [Related]
6. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121 [TBL] [Abstract][Full Text] [Related]
10. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells. Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041 [TBL] [Abstract][Full Text] [Related]
11. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation. Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907 [TBL] [Abstract][Full Text] [Related]
12. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Stahl A; Mueller BM Int J Cancer; 1997 Mar; 71(1):116-22. PubMed ID: 9096674 [TBL] [Abstract][Full Text] [Related]
13. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? Deng G; Curriden SA; Wang S; Rosenberg S; Loskutoff DJ J Cell Biol; 1996 Sep; 134(6):1563-71. PubMed ID: 8830783 [TBL] [Abstract][Full Text] [Related]
14. Variability in the expression of urokinase receptor (CD87) mutants on cells: relevance to cell adhesion. Kanse SM; Chavakis T; Kuo A; Bdeir K; Cines DB; Preissner KT Cell Biochem Funct; 2004; 22(4):257-64. PubMed ID: 15248186 [TBL] [Abstract][Full Text] [Related]
15. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. Okumura Y; Kamikubo Y; Curriden SA; Wang J; Kiwada T; Futaki S; Kitagawa K; Loskutoff DJ J Biol Chem; 2002 Mar; 277(11):9395-404. PubMed ID: 11773078 [TBL] [Abstract][Full Text] [Related]
16. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680 [TBL] [Abstract][Full Text] [Related]
17. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site. Ploug M Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416 [TBL] [Abstract][Full Text] [Related]
18. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. Ploug M; Rahbek-Nielsen H; Ellis V; Roepstorff P; Danø K Biochemistry; 1995 Oct; 34(39):12524-34. PubMed ID: 7548000 [TBL] [Abstract][Full Text] [Related]